NADP isocitrate dehydrogenase 1 (isocitrate dehydrogenase [NADP] cytoplasmic, IDH1)
Jump to navigation
Jump to search
Function
- catalyzes reversable conversion of isocitrate to 2-oxoglutarate
isocitrate + NADP+ <--> 2-oxoglutarate + CO2 + NADPH
Cofactor: binds 1 Mg+2 or Mn+2 per subunit
Structure
- homodimer
- belongs to the isocitrate & isopropylmalate dehydrogenases family
Compartment
Pathology
- IDH1 gene mutation
- IDH1 R132H mutation, with codeletion of 1p & 19q seen in a case of recurrent oligodendroglioma[3]
- IDH1-mutation in acute myeloid leukemia (AML)[4]
- addition of IDH1 inhibitor ivosidenib (Tibsovo) to azacitidine increases survival 3-fold[4]
Pharmacology
- ivosidenib inhibits mutant IDH1 in relapsed or refractory acute myeloid leukemia (AML) with IDH1 gene mutation
- vorasidenib (Servier) inhibits mutant IDH1 investigational treatment of gliomas with IDH1 gene mutation
More general terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/O75874.html
- ↑ Wikipedia, isocitrate dehydrogenase entry http://en.wikipedia.org/wiki/isocitrate_dehydrogenase
- ↑ 3.0 3.1 Chi AS, Cahill DP, Larvie M, Louis DN Case 38-2016 - A 52-Year-Old Woman with Recurrent Oligodendroglioma. N Engl J Med 2016; 375:2381-2389. December 15, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27974037 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1610101
- ↑ 4.0 4.1 4.2 Ingram I Upfront IDH1 Inhibitor Triples Survival in Older AML. Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy. MedPage Today December 11, 2021 https://www.medpagetoday.com/meetingcoverage/ashhematology/96149